Navigation Links
Lotus Pharmaceuticals Announces Change of Directors
Date:12/21/2010

BEIJING, Dec. 21, 2010 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), today announced the resignation of four members of its board of directors and the subsequent appointment of four new directors.

Mr. Michael Toups, Mr. Lijun Fan, Mr. Zhaohui Li, and Mr. Jun Lu have been appointed to serve on the Company's board of directors. They will replace current directors Ms. Li Ping, Mr. Liu Jin, Ms. Xian Xuemei, and Mrs. Song Zhenghong.

Lotus' Chairman and Chief Executive Officer, Mr. Zhongyi Liu, commented, "We sincerely appreciate the contribution that Ms. Li, Mr. Liu, Ms. Xian and Mrs. Song have made to Lotus over the years, and we wish them great success in their future endeavors. We felt that this strategic decision was necessary to further strengthen our management team as we prepare to apply for a listing on a national securities exchange in the near future. We are excited to add Mr. Toups, Mr. Fan, Mr. Li, and Mr. Lu, all of whom are seasoned business professionals in their respective fields, to our board of directors. We believe they are well-qualified and will provide valuable guidance and advice to the Company."

Michael Toups is an accounting and corporate finance executive with 20 years of experience in senior management with specialties in business strategy, M&A and international trade. He has middle-market corporate finance experience across a variety of industries as both principal and advisor and has served in roles as the CFO, COO, and director of private and publicly traded companies. His expertise includes PCAOB audits, SEC reporting, Sarbanes-Oxley compliance and investor relations. Mr. Toups is also well-versed in Chinese business practices and has directed strategic planning for Asia-based companies for over 12 years.

Most recently, Mr. Toups has served as the CFO for Longwei Petroleum Investment Holding Limited, a China-based petroleum distributor. Mr. Toups also currently serves as the CFO of China Bilingual Technology & Education Group, a China-based education company operating K-12 private boarding schools. Mr. Toups holds an MBA in Finance from the University of Notre Dame and a BBA in Finance from Texas Christian University.

Mr. Lijun Fan currently serves as President and CEO of Jolyvia International, Inc., which manufactures independent brand cosmetics and operates Jolyvia Beauty SPA national chain stores in China. From 2003 to 2009, he was the general manager and director of Jourdeness International Inc., where he was responsible for the expansion of direct-to-consumer cosmetics and beauty chain SPA in China. Previously, he was the general manager and founder of Zhuhai Yi Sheng Development Co., a sales distributor for cosmetics and personal care products, and sales manager for Zhuhai Dong Da Biological Pharmaceutical Co. Mr. Lijun holds a Bachelor of Science degree in biology from Jinan University.

Since 1998, Mr. Zhaohui Li has served as a professor and the director of the Department of Assisted Reproduction at China Three Gorges University School of Medicine. Previously, Mr. Zhaohui has served as Assistant to the General Manager and Director of Marketing at Guangdong Zhuhai Dong Da Biological Pharmaceutical Co. and General Manager at Guangdong Zhuhai Dong Wu Pharmaceutical Co. He holds a Master of Science degree from the Institute of Biochemistry at the Chinese Academy of Sciences and a Bachelor of Science degree in biology from Peking University.

Mr. Jun Lu has been the head of research and development for Lotus Pharmaceuticals since 2006 and previously worked at Beijing Double-Crane Pharmaceutical Co., Ltd. Mr. Lu holds both a master's and a bachelor's degree in pharmacy from ShenYang Pharmaceutical University. His research focuses on various new pharmaceutical dosage forms, especially in osmotic pump-controlled release. Mr. Lu has published six papers in well-known peer-reviewed journals and filed four patents, two of which have been granted.

About Lotus Pharmaceuticals, Inc. Lotus Pharmaceuticals, Inc. is a fast-growing, profitable developer and producer of drugs and a licensed national seller of pharmaceutical items in the People's Republic of China (PRC). Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular diseases, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.

Information Regarding Forward-Looking StatementsExcept for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product demand, market competition, and risks inherent in our operations. These and other risks are described in our filings with the U.S. Securities and Exchange Commission.Contacts:At the Company:Xing Shen, Ph.D.
VP of Corporate Development
Lotus Pharmaceuticals, Inc.
Ph: 415-690-7688
Email: shen@lotuspharma.com
Web: http://www.lotuspharma.comInvestor Relations:Dave Gentry, U.S.
RedChip Companies, Inc.
Tel: +1-800-733-2447, Ext. 104
Email: info@redchip.com
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lotus Pharmaceuticals Announces Update on Land in Inner Mongolia
2. Lotus Pharmaceuticals Announces Conference Call to Discuss Third Quarter 2010 Financial Results
3. Lotus Pharmaceuticals Preparing to Apply for National Exchange Listing
4. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
5. Lotus Pharmaceuticals Announces Two Senior Management Appointments
6. Lotus Pharmaceuticals Announces Engagement of RedChip Companies to Lead Public and Investor Relations Efforts
7. Lotus Pharmaceuticals Enter R-Bambuterol(R) Clinical Trial I
8. Lotus Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results
9. Lotus Completed R-Bambuterols Pilot Scale Production for Clinical Trials
10. Lotus Pharmaceuticals Terminates SEDA
11. Lotus Pharmaceuticals to Present at Global Hunter Securities 2010 China Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical ... the company with their  2017 New Product Innovation Award ... on extensive primary and secondary medical device market research by ... through its first-to-market OTC, drug-free pain relief product, the AVACEN ... approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... Texas , Oct. 11, 2017  Caris Life ... focused on fulfilling the promise of precision medicine, today ... has joined Caris, Precision Oncology Alliance™ (POA) as its ... cancer centers, the St. Jude Crosson Cancer Institute will ... advance the use of tumor profiling, making cancer treatment ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
Breaking Medicine News(10 mins):